Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2457

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2457). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622457)

Label for Lisdexamfetamine Dimesylate Capsules 60 mg, oral dosage form, containing 100 capsules. The label indicates the NDC 72162-2457-1 and states the product is Rx only. It is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA and manufactured by Purdue Pharma L.P. Storage and dispensing instructions are also included along with QR codes for package insert and dosage information.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

Chemical structure of lisdexamfetamine dimesylate showing the molecular formula with amino, phenyl, and sulfonate groups as part of the compound's detailed chemical diagram.*

FDA Label Image

Figure 1 (Lisdexcaps 02)

A forest plot chart showing fold change and 90% confidence intervals for Cmax and AUC pharmacokinetic parameters across special populations, including gender, age groups (65-74 years, >=75 years), varying degrees of renal impairment (mild, moderate, severe), and end-stage renal disease. The horizontal axis represents the change relative to reference, spanning from 0.0 to 2.5.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

A forest plot chart showing fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC. The chart compares changes relative to reference for three drugs: Guanfacine, Venlafaxine, and Omeprazole. The x-axis represents change relative to reference, ranging from 0.0 to 2.0.*

FDA Label Image

Figure 3 (Lisdexcaps 04)

A scatter plot with error bars showing the fold change and 90% confidence intervals in pharmacokinetic parameters Cmax and AUC for various interacting drugs relative to a reference. Drugs listed include Guanfacine, Venlafaxine, caffeine (CYP1A2 substrate), Dextromethorphan (CYP2D6 substrate), Omeprazole (CYP2C19 substrate), and Midazolam (CYP3A substrate). The x-axis represents change relative to reference ranging from 0 to 2.*

FDA Label Image

Figure 4 (Lisdexcaps 05)

A line graph showing LS Mean (SE) SKAMP Deportment Scores over time post-dose (in hours) comparing Lisdexamfetamine versus placebo. The graph presents drug effect on behavior scores from 0 to 13 hours after dosing, with Lisdexamfetamine scores lower than placebo throughout most of the time points.*

FDA Label Image

Figure 5 (Lisdexcaps 06)

A line chart comparing the proportion of subjects with relapse or treatment failure over time for Lisdexamfetamine versus placebo. The x-axis represents time in days after randomization (0 to 55 days), and the y-axis shows the percentage of subjects with relapse or treatment failure (0% to 100%). The solid line represents Lisdexamfetamine and shows a lower and slower increase in relapse compared to the placebo, indicated by the dashed line which rises more steeply and reaches nearly 70%.*

FDA Label Image

Figure 6 (Lisdexcaps 07)

A line graph showing LS Mean (SE) PERMP Total Scores over time post-dose up to 14 hours. Two lines represent Lisdexamfetamine and Placebo. The Lisdexamfetamine line shows higher scores with a rising trend post-dose, while the Placebo line remains lower with a gentler increase. Error bars indicate variability at each time point.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

A Kaplan-Meier survival plot showing the proportion of subjects with relapse or treatment failure over time (days after randomization). Two lines compare placebo (dashed) and lisdexamfetamine (solid), illustrating a higher proportion of relapse/treatment failure in the placebo group compared to lisdexamfetamine over approximately 35 days.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

A line graph comparing the proportion of subjects with relapse over time (days after randomization) between Lisdexamfetamine and placebo groups. The solid line represents Lisdexamfetamine, showing a low relapse proportion, while the dashed line represents placebo with a higher relapse proportion. The chart includes subject counts at risk at various time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.